Appointments at Jennerex, a new KV subsidiary and Takeda – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Vice president Pharmacology Pharmacy

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Jennerex, a new KV subsidiary and Takeda.

Jennerex ​has hired Mark Backer​ to the newly created position of senior vice president (SVP), technical operations. Backer will be responsible for all aspects of chemistry, manufacturing and controls (CMC) in support of Jennerex’s lead and pipeline products.

Before joining Jennerex Backer worked as a principal of Biologics Technical Consulting and earlier in his career held positions at Vaxart, Eli Lilly and Genentech.

Mark Hartman ​has been named as president of Nesher Pharmaceuticals​, the new generic marketing subsidiary of KV Pharmaceutical​. Hartman has previously worked at Wockhardt USA, Dr Reddy’s Laboratories, Watson Laboratories and Alpharma.

Takeda Pharmaceutical ​has appointed Anna Protopapas ​as head of its new Global Business Development (GLBD) organisation. Protopapas was previously in charge of business development at Millennium and has also worked at Proctor & Gamble.

Eric Richman ​has taken the positions of president and CEO​at PharmAthene​ on a permanent basis, having held the roles on an interim-basis since May. Richman joined PharmAthene in 2003 having previously worked at MedImmune and HealthCare Ventures.

MAP Pharmaceuticals ​has named Thomas McCracken ​as VP, intellectual property. McCracken has previously worked at Durect, PowderJect Pharmaceuticals and in a biopharm-focused private patent law practice.

Tony Horton ​has been appointed as VP of quality assurance at Pharmaceutics International​. Horton has 35 years of quality assurance experience working at companies including BenVenue, Mylan Laboratories, Gensia Sicor Pharmaceuticals, Fujisawa and Baxter Labs.

Ancora Pharmaceuticals ​has added Florian Schödel ​to its team of scientific advisors. Schödel joined Merck Research Labs in 1996 having previously worked at the Max-Planck Institute for Biochemistry.

Related topics Markets & Regulations

Related news

Show more

Follow us


View more